Skip to main content
Clinical Trials/CTRI/2024/07/070510
CTRI/2024/07/070510
Not yet recruiting
未知

Observational study to assess efficacy and safety of Bifidobacterium longumW11 plus Fructooligosaccharide combination in patients with irritable bowel syndrome (IBS) - NI

Abbott India Ltd0 sites0 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Health Condition 1: K519- Ulcerative colitis, unspecified
Sponsor
Abbott India Ltd
Status
Not yet recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • Patients of either sex, aged between 18 and 60 years
  • OPD Patients with confirmed diagnosis of IBS with any of the three subtypes (viz IBS D/IBS C/IBS M)
  • Patients with no improvement in symptoms despite treatment with antispasmodics

Exclusion Criteria

  • Patients will be excluded if they have severe respiratory insufficiency organic brain damage sleep apnea syndrome severe acute or chronic
  • hepatic insufficiency (risk of occurrence of encephalopathy) myasthenia gravis chronic psychosis major depressive episodes
  • phobic or obsessional states or dementia
  • Patients with other pre\-existing GI disorders GI surgery abnormal upper and lower GI endoscopy finding family history of colon cancer or inflammatory bowel disease symptoms that discriminate lower GI organic diseases from IBS such as blood in stool nighttime symptoms
  • that cause sleep disturbance unintentional weight loss or change in typical IBS symptoms such as new and/or different pain and alcohol or drug\-dependency

Outcomes

Primary Outcomes

Not specified

Similar Trials